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The enterochromaffin-like (ECL) cells represent the predominant endocrine cell population
in the acid-producing part of the stomach of both experimental animals and man. These cells
actively produce and store histamine in addition to an anticipated but as yet unidentified
peptide hormone and are under the control of gastrin. An acute gastrin stimulus causes
exocytosis of the cytoplasmic granules/vesicles (and release of histamine and activation of the
histamine-forming enzyme, histidine decarboxylase), while a more sustained gastrin stimulus
causes first hypertrophy and then hyperplasia of the ECL cells in the rat (at most, a fivefold
increase in the cell number). These effects can be demonstrated following infusion ofgastrin or
following an increase in the concentration of circulating gastrin of endogenous origin. The
growth of the ECL cells reflects an accelerated self-replication rate. As studied in the rat, the
self-replication rate is accelerated quite soon after induction ofhypergastrinemia (blockade of
acid secretion), the rate is maximally elevated within two weeks and then declines to control
values at ten and 20 weeks despite the sustained hypergastrinemia. Lifelong hypergastrinemia
in rats is associated not onlywith ECL-cell hyperplasia but also with an increased incidence of
ECL-cell carcinoids. Recently, we could show that a-fluoromethylhistidine, which is a suicide
inhibitor ofhistidine decarboxylase, effectively depletes the ECLcellsofhistamine and that the
histamine-depleted ECL cells respond to gastrin with hyperplasia in a manner identical to
normal ECL cells. Other factors beside gastrin seem to participate in the control of ECL-cell
function and proliferation. Although exogenous somatostatin is known to suppress the activity
of the ECL cells, we have failed to obtain evidence that the somatostatin cells in the oxyntic
mucosa play a role in the physiological control of the ECL cells. The vagus, however, is
important for the ability ofthe ECL cells to respond to gastrin. This conclusion is based on the
observation that vagal denervation suppresses the hyperplastic response of the ECL cells to
gastrin. Porta-cava shunting, on the other hand, greatly enhances the responsiveness of the
ECL cells to gastrin. The mechanism behind this effect is unknown.
INTRODUCITION
It is perhaps not widely known that not only the antrum but also the acid-
producing part ofthe stomach is rich in endocrine cells. Most ofthe endocrine cells
in the latter region remain unidentified in functional terms. Interest in these cells
increased greatly with the observation that long-term treatment with effective
inhibitors of gastric acid secretion (proton pump inhibitors and histamine H2-
receptor antagonists) caused hyperplasia ofone ofthe endocrine cell populations in
the acid-producing mucosa, the so-called enterochromaffin-like (ECL) cells, and
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that there were reasons to believe that carcinoids could develop from these cells in
response to lifelong hypergastrinemia.
Thus, the ECL cell of the stomach has moved from relative obscurity to fame, if
such aword can be used to describe the fascinated but somewhat bewildered interest
that this cell has attracted for the last five years or so. The fascination can be
accounted for by the tendency of the ECL cell to generate tumors in situations
characterized by hypergastrinemia, and the bewilderment reflects our ignorance of
its normal functional significance. The present paper reviews the current evidence
that seems to indicate that the ECL cells represent an important endocrine cell
system and that they are under the control ofgastrin.
OCCURRENCE, TOPOGRAPHY, AND ULTRASTRUCTURAL FEATURES
OF THE ECL CELL
The ECL cells represent one of several different endocrine cell populations that
have been identified in the acid-producing part ofthe gastric mucosa [1-8]. It should
be pointed out that the endocrine cells in the acid-producing gastric mucosa are
quite numerous (constituting 1 and 2percentbyvolume in man and rat, respectively)
and that consequently this part ofthe stomach represents a quantitatively impressive
endocrine organ. As such, the acid-producing part of the stomach remains largely
unexplored. On the basis oftheir histochemical features and ultrastructure, it can be
assumed that the different endocrine cell populations produce peptide hormones,
although very little is known about the nature ofthese anticipated hormones. While
four different endocrine cell types have been demonstrated in the oxyntic mucosa of
the rat, at least five endocrine cell populations have been identified in man [4,5,8]. In
all species studied, the ECL cells form the predominant endocrine cell population
[8-10], and in all species they seem to be restricted to the oxyntic mucosa. In man,
theymake up 35 percentofthe total numberofendocrine cells in the oxyntic mucosa
[11,12]; in the rat, the corresponding figure is 65 percent [8]. The ECL cells, which
are usually small and elongated, or irregularly shaped, are characterized by the
presence of numerous large electron-lucent vesicles in the cytoplasm [2,5,6,10,13]
(Fig. 1). Some of these vesicles have an electron-dense core, and, in a few of these
vesicles, the core is so predominant that the organelle should probablybe referred to
as a granule rather than a vesicle. There seems to be some species variation in the
appearance ofthevesicles; inman, forinstance, most ofthem have an electron-dense
core. The ECL cells can be demonstrated by the fact that they produce and store
histamine [14], which can bevisualized immunocytochemically by the use ofantibod-
ies to histamine [9] (Fig. 2) or to the histamine-forming enzyme [15]. ECL cells or
ECL-cell equivalents seem to occur in the acid-producing gastric mucosa ofavariety
ofspecies, from cartilaginous fish to man [9]. They are particularly numerous in the
rat and chicken, and they are relatively few in dog, monkey, and man. Their
topographic distribution within the acid-producing mucosa differs among different
classes of animals. In mammals, they occur in the basal third or basal half of the
glands; in birds, they are found in the periphery of the spherical compound glands
that make up the mucosa of the proventriculus. In amphibia and lizards, they occur
at the base ofthe foveolae in the neckregion, and, infish, they are often foundwithin
the surface epithelium [9].
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FIG. 1. Electron micrograph of an ECL cell in
-i ; ^. > G R b rat stomach with the characteristic vesicular-type
'W 3 a ; l_1i g cytoplasmic granules, some of which display a
small electron-dense core, x6,000.
THE ECL CELL RESPONSE TO GASTRIN
In all species that have been studied so far, the ECL cells have been found to
respond to gastrin. This process has been studied in detail in the rat [16-19]. The
response is manifested in several ways (Fig. 3). Elevated circulating gastrin concen-
tration is reflected in prompt histamine release and increased histidine decarboxyl-
ase activity. If the gastrin stimulus is sustained, the ECL cells will respond with
hypertrophy; this response is manifested within a few days ofgastrin challenge [13].
They respond also with hyperplasia; this response requires weeks to months to
develop [19]. Theseresponsesofthe ECLcellshavebeendemonstrated inexperimen-
tal animals that have been subjected to treatments that either lower or raise the
circulating concentrations of gastrin. In addition, gastrin stimulates growth of the
oxyntic mucosa, and lack ofgastrin is associated with atrophy ofthe oxyntic mucosa.
FIG. 2. Histamine-immunoreactive
ECL cells in the acid-producing part of
the rat stomach (transversesection, mu-
-L, _ ! cosal surface upward). Mast cells are
relatively few and located at the muco-
sal surface and in the submucosa and
muscle coat. The ECL cells are located
basally in theglands. The immunoreac-
tive cells are demonstrated by dark-
field microscopy following peroxidase-
antiperoxidase staining, x 100.
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FIG. 3. Aschematic outline of some recognized effects ofgastrin on the ECLcells,
with an approximate time scale indicating how long the hypergastrinemia has to be
sustained in order for the various effects to become manifest.
The induction of endogenous hypergastrinemia by antrum exclusion [20] or by
partial removal of the acid-producing part of the stomach (fundectomy or corpec-
tomy) [21] resulted in an increased ECL-cell density, whereas hypogastrinemia
induced by antrectomy had the reverse effect [22,23]. Administration of effective
inhibitors ofacid secretion, such as H2-receptor antagonists like ranitidine or proton
pump inhibitors like omeprazole [23-25], raised not only the level of circulating
gastrin but also the ECL-cell number (Fig. 4). Also, hypergastrinemia induced by
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FIG. 4. ECL-cell hyperplasia following ten weeks of daily administration of large doses of omepra-
zole. Control rat, A. Omeprazole-treated rat, B. The ECL cells are visualized by histamine
immunostaining (peroxidase-antiperoxidase), x200.
Enlargement of endoplasmic reticulum
Enlargement of Golgi area
Increased cell size
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continuous infusion of exogenous gastrin for 28 days in the rat resulted in ECL-cell
hyperplasia [26].
Inorder to learn whether the mechanism leading to hyperplasiawas an increase in
the ECL-cell mitotic activity or a passive mechanism such as increased ECL-cell life
span orwhether the hyperplasia was caused by accelerated stem cell differentiation,
specific immunocytochemistry and autoradiography were combined to observevaria-
tions in the ECL-cell kinetics. The DNA in rat ECL cells can be radiolabeled using
3H-thymidine [27]. The proportion of ECL cells that become labeled with 3H after a
single injection of3H-thymidine is referred to as the ECL-cell labeling index (LI). In
normal rats, the ECL cells display greater LI during the night than during the day,
coinciding with the time when rats have high circulating gastrin levels. Nine days
after starting a blockade ofacid secretion by a high-dose treatment with omeprazole
in male rats, which leads to hypergastrinemia, we observed an eightfold increase in
the ECL-cell LI, while, at the same time, mitotic figures in ECL cells were quite
numerous [27]. Hence, we conclude that activation of self-replication is the mecha-
nism increasing the ECL-cell number in response to omeprazole-evoked hypergas-
trinemia (see also [28]). In fact, we observed a positive correlation between the
ECL-cell proliferation rate (LI) and the circulating gastrin levels in the animals of
that experiment [27].
In another study, male rats were submitted to surgery in order to induce endoge-
nous hypergastrinemiathrough antrumexclusionorhypogastrinemiathroughantrec-
tomy [29]. A 52 percent increase in ECL-cell number was observed six weeks after
antrum exclusion; the number decreased by 17 percent after antrectomy. The
ECL-cell LI was doubled following antrum exclusion, while it was reduced to less
than 25 percent ofits value in control rats after antrectomy. Again, there was a good
correlationbetween the ECL-cellproliferation rate and thecirculatinggastrin levels.
Sustained endogenous or exogenous hypergastrinemia of comparable magnitude
was induced in female rats [30]. The rise in circulating gastrin was induced either
throughoral administrationof80 p,mol/kgofomeprazoleonce dailyorbysubcutane-
ous infusion of 1,200 ,umol/kg/day of ranitidine through osmotic mini-pumps. Rat
gastrin-17 was administered through subcutaneously implanted mini-pumps at a
dose of 60 nmol/kg/day. Previously, antrectomized rats were also given either
omeprazole or the solvent. After 12 days, the ECL-cell density as well as the gastrin
levels had increased in thegroupswith an intact antrumreceivingantisecretorydrugs
or gastrin, whereas the number of ECL cells had decreased in the antrectomized
groups. Accordingly, treatment with ranitidine as well as with omeprazole or
exogenous gastrin increased the proliferative parameters in the ECL-cell population
to values reaching four to seven times the control value (see also [31]). In the
antrectomized rats, with or without omeprazole, the ECL-cell LI was lower than in
the intact rats. Again, a significant correlation was observed between circulating
gastrin levels and the proliferative activity ofthe ECLcells (Fig. 5).
All these experimental results favor the hypothesis that circulating gastrin is a
major trophic factor for the ECL-cell population. Whenever hypergastrinemia is
induced, regardless ofwhether acid secretion is stimulated or depressed, there is an
increase in the mitotic activity of the ECL cells, followed by the development of
ECL-cell hyperplasia. Hence, gastrin appears to play a central role in the kinetic
control notonlyofthe oxynticmucosal stem cellsbut also ofthe ECLcells, the major
endocrine cell population in this part ofthe stomach. The results seem tojustify the
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FIG. 5. ECL-cell labeling index (LI) as a function ofthe circulating gastrin level at the time ofsacrifice.
Antrectomized rats were operated six weeks before entering the study. The rats were treated with
omeprazole (80 ,umol/kg/day), ranitidine (1,200 p.mol/kg/day), rat gastrin-17 (60 nmol/kg/day), or
solvent for 12 days. Ten to 11 ratswere in each group. The ratswere killed between 10 A.M. and noon, one
hour after a single intraperitoneal injection of3H-thymidine (1 mCi/kg). There was a positive correlation
(p < 0.05) between the ECL-cell LI and the plasma gastrin concentration [30].
following conclusions: (1) The ECL-cell density reflects the circulating gastrin
concentration. (2) Large doses of effective and long-acting inhibitors of acid secre-
tion cause proliferation of ECL cells through the ensuing hypergastrinemia. Also,
hypergastrinemia of a moderate degree is associated with hyperplastic manifesta-
tions. This fact was demonstrated in obese Zucker rats, who had a two- to threefold
increase in the serum gastrin concentration compared to lean rats. At 18 months of
age, the obese (but not the lean) rats displayed both linear and micronodular
ECL-cell hyperplasia [32].
THE DEVELOPMENT OF ECL-CELL TUMORS:
THE GASTRIN CONCEPT
Lifelong administration (two years) of high doses of effective antisecretory drugs
to rats is associated with the development ofECL-cell tumors, i.e., ECLoma, gastric
carcinoids [33-43]. Changes rangedfrom a diffuse hyperplasia throughfocal aggrega-
tion of cells to structures of more solid appearance, the latter manifestations
occurring afterlong-lasting treatment only. Inviewofthe known stimulating effectof
gastrin on the ECL cells, the so-called gastrin concept was formulated in order to
explain the hyperplasia and the development of carcinoids. The gastrin concept
maintains that effective inhibition of gastric acid secretion abolishes luminal acid
feedback inhibition of the antral gastrin cells, leading to hypergastrinemia, which in
turn activates the ECL cells, producing first diffuse and later on focal ECL-cell
hyperplasia with micronodules and finally carcinoids [18,19,44] (Fig. 6). The se-
quence of events described above is not drug-specific, in that many different agents
produce it (see, e.g., [45]). The common denominator is that all the drugs produce
hypergastrinemia. Theview that gastrin is an important causative factor is supported
by the fact that partial fundectomy (corpectomy) (25 percent of the acid-producing
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general hyperplasia FIG. 6. A schematic outline of the
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- micronodules the development of gastric ECL-cell
- carcinolds tumors.
mucosa remaining), which results in sustained hypergastrinemia, causes ECL-cell
hyperplasia [21], followed bythe development ofgastric carcinoids [46]. The "gastrin
concept" provides a rational explanation to account for the development ofECL-cell
hyperplasia in the rat in response to treatment with powerful anti-secretagogues.
The development of ECLoma in the rat stomach after two years ofdrug administra-
tion is, however, lesswell accounted for. The stimulus behind the development ofthe
ECLoma is thought to be the hypergastrinemia (rather than the achlorhydria), and
there is no evidence that, for instance, ranitidine or omeprazole are directly acting
carcinogens or co-carcinogens. One question which has not yet been addressed
experimentally is whether gastrin acts directly to cause ECL-cell hyperplasia or
whether it does so indirectly, through the mediation of some local growth promoter.
Although gastrin, directly or indirectly, may be able to stimulate growth oftumors, it
appears unlikely that gastrin per se induces oncogenic transformation. In this
context, it may be of interest to note that the ECL-cell density in the rat increases
with age. In fact, ECL-cell hyperplasia with micronodules has been reported in aging
rats [47], and a few cases ofspontaneous ECL-cell tumors are on record [48]. Hence,
senescence maybe a contributing factorbehind the development ofECL-cell tumors
in the rat, possibly in combination with high concentrations ofcirculating gastrin.
An analogous situation exists in patients with achlorhydria as a result of chronic
atrophic gastritis. These patients usually have high levels of circulating gastrin.
Diffuse or focal hyperplasia of argyrophil cells (which include the ECL cells) is a
characteristic feature of many such cases, and there seems to be a correlation
between the circulating gastrin concentration and the degree of argyrophil cell
hyperplasia [49-56]. Gastric carcinoids, which on the whole are rare tumors, are not
uncommon in such patients [53,54,57,58]. They are often multiple and associated
with hyperplasia ofargyrophil cells in the surrounding tissue. Gastric carcinoids have
been found in another category of hypergastrinemic patients: namely, those with a
gastrin-producing tumor (Zollinger-Ellison syndrome) [59-61]. Thus, there also
seems to be a link between hypergastrinemia and an increased incidence of gastric
carcinoids in man. Gastric carcinoids, however, have lowmalignant potential and are
rare in patients, even in situations of massive hypergastrinemia associated with
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gastrinoma. There are reports indicating that the ECL-cell hyperplasia, including
micronodules, in such patients disappears after antrectomy (or after removal of the
gastrinoma), and there is evidence thatgastriccarcinoidsmayalsodisappear [62-65].
When rats are given high doses of omeprazole daily, the ECL-cell LI starts to
increase after two days and reaches a maximal level after about nine to ten days,
which should be enough to explain the gastrin-evoked ECL-cell growth [27]. If the
administration of omeprazole is interrupted after 16 days of administration, the
ECL-cell LI is rapidly suppressed, in fact, to levels below those seen in the control
rats [66]. In another experiment, omeprazole treatment rapidly raised the serum
gastrin concentration to aplateau andprogressivelyraised the ECL-cell densityup to
10-20 weeks of treatment; thereafter it reached a plateau, while the ECL-cell LI
reached a peak after one to two weeks of omeprazole treatment. The peak in the
ECL LI was followed by a decline tovalues similar to or actuallybelow those seen in
normal rats [67], perhaps because ofthe formationoflocal anti-trophic stimuli in the
mucosa or in the ECL cells themselves. There are several points of interest here.
Apparently, it is possible to have a progressive and subsequently maintained ECL-
cell hyperplasia without accelerated mitosis frequency, possibly because of a pro-
longed life span of the cells or, less likely, because ofrecruitment of ECL cells from
stem cells. Second, the fact that the histidine decarboxylase activity was maintained
at a very high level throughout the experiment is interesting, because it means that
the gastrin-induced activation ofthe ECLcells ismaintained eventhough the trophic
stimulus ofgastrin, reflected in the elevated LI, is offset. Perhapswe are dealingwith
two gastrin receptors, one handling activation of the cell, another the induction of
mitosis-or we are dealing with two post-receptor pathways, one functioning at all
times, the other being offset with long-term exposure to gastrin. According to the
classical gastrin concept, ECLomas develop against abackground offirst diffuse and
then focal ECL-cell hyperplasia as a result of long-standing hypergastrinemia.
Previously, it had been assumed that a permanently elevated mitotic index, perhaps
in combination with an increased risk ofmutation because of old age, could explain
the ECL-cell tumor development. Now it seems that an explanation has to be found
elsewhere.
One issue that has been raised recently is whether histamine in the ECL cells is
important for the growth of the ECL cells and/or for the growth of the oxyntic
mucosa, implying that the ECL cell and its histamine might mediate the gastrin-
evoked trophic response ofthe mucosa [68]. One way to approach this question is to
eliminate all histamine from the ECL cells and observe the consequences. We
decided to use ot-fluoromethylhistidine (ot-FMH), which is a so-called suicide inhibi-
tor of histidine decarboxylase [69] and which effectively blocks the production of
histamine in the ECL cells. It could be shown by immunocytochemistry that a-FMH
depletes histamine from the ECLcells (Fig. 7) but not from the mast cells, which are
few in the oxyntic mucosa ofthe rat. The result was a loss ofmore than 80 percent of
oxyntic mucosal histamine [70]. The effect of histamine depletion on the trophic
responses evoked by omeprazole-induced hypergastrinemia for six weeks was stud-
ied. Histamine was predictably lost from the ECL cells in the a-FMH-treated rats,
while the concentration ofoxyntic mucosal histamine was increased in the rats that
received omeprazole alone. The growth-promoting effect of omeprazole-evoked
hypergastrinemia on the gastric mucosa and on the ECL cells in particular was
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FIG. 7. Histamine immunostaining. Rat stomach, oxyntic mucosa, transverse section.
Treatment with a-fluoromethylhistidine prevents the formation of histamine and depletes
histamine from the ECLcells (but not from the mast cells) in the rat stomach. This effect is
reflected in the loss ofhistamine immunostaining, A. Control rat for comparison, B, x200.
unaffected by a-FMH pre-treatment [68]. In fact, the ECL-cell number was in-
creased by gastrin stimulation to the same degree, regardless of whether the ECL
cells contained histamine or not. Hence, it appears that ECL-cell histamine does not
play a role in gastrin-evoked growth stimulation; however, the ultrastructure of the
ECLcellswasgreatlyaffectedbya-FMH (Fig. 8). Thevesicleswere small and greatly
reduced in number. The granules remained, apparently unaffected, suggesting
perhaps that histamine is located in thevesicles rather than in the granules [70].
OTHER FACTORS BESIDE GASTRIN CONTROL THE ECL CELLS
Although available evidence suggests that gastrin represents the major stimulus,
gastrin is not the only factor of importance for the control of the ECL cells.
Somatostatin released from adjacent somatostatin cells could interfere with the ECL
cells in a paracrine fashion, and exogenous somatostatin effectively suppresses the
activity of the ECL cell and the growth of the ECL cells. We have not been able to
demonstrate that gastrin activates the somatostatin cells or causes them to grow,
although there is some evidence that they have a gastrin receptor [71]. On the
contrary, somatostatin cells in the oxyntic mucosa are reduced in number in
hypergastrinemic rats and increased in number in antrectomized rats [72]. The
possibility cannot be excluded that gastrin inhibits the somatostatin cells in the
oxyntic mucosa, thereby stimulating ECL-cell activity and proliferation. There is
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granules in the cytoplasm, x6,000.
some evidence that the somatostatin cells have not only gastrin receptors but also
CCK-Areceptors [71,73-75]. The ECLcells respond to CCKvia an action on gastrin
or CCK-B receptors [76]. If the somatostatin cells were to be activated by CCK to
release somatostatin to suppress the activity (and growth) of the ECL cells, then
CCK-A receptor blockade should enhance the response of the ECL cells to CCK.
This hypothesis could not be confirmed. Both gastrin and CCK activated the ECL
cells to the same extent, despite CCK-A receptor blockade [76], using maximally
effective doses ofthe CCK-A receptor antagonist devazepide.
The vagus plays a role in the control ofthe oxyntic mucosal growth, including the
ECL cells. This fact can be demonstrated by unilateral vagotomy of rats. If the two
sides ofthe stomach, the denervated and thevagally intact sides, are compared eight
to ten weeks after denervation, it is apparent that the vagally denervated side ofthe
mucosa is thinner and that the ECL cells are fewer than on the intact side [77,78]. If
unilaterally vagotomized rats are exposed to omeprazole, the serum gastrin concen-
tration is elevated, as in omeprazole-treated control rats, but tenweeks later there is
a cleardifference in the appearance ofthe mucosa on thevagally denervated and the
intact sides. On the intact side, it is thick and prominent, while, on the denervated
side, it is thin and inconspicuous. Not only the mucosa in general but also the ECL
cells are affected by the vagotomy. The ECL-cell hyperplasia is much less conspicu-
ous on the denervated side than on the intact side. The results are compatible with
theview that anintactvagal innervationisrequiredforafull growth-promoting effect
ofgastrin. Thus, omeprazole-evoked hypergastrinemia fails to evoke the anticipated
growth of the ECL cells and of the mucosa following unilateral vagotomy [79]. It is
not known whether these rats are less likely to develop carcinoids than are vagally
intact rats. It is also not known whether hypergastrinemic patients would benefit
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fromvagotomyin terms oflowerdegree ofECL-cell hyperplasia and lower incidence
ofgastric carcinoids.
Porta-cava shunting (PCS) is known to increase the ECL-cell density forunknown
reasons [22,80]. This operation does not increase the serum gastrin concentration,
but antrectomy prevents the effect of PCS, suggesting that, in one way or another,
gastrin contributes to the response [80]. In fact, the results suggest that the number
ofgastrin receptors on the ECL cells are increased severalfold by PCS and that, for
this reason, the ECL cells respond to gastrin in an exaggerated manner [80]. The
reason for the upregulation of the gastrin receptors is unknown. Omeprazole
treatment elevates the serum gastrin concentration in the PCS rats much like that in
the sham-operated rats, but ten weeks of omeprazole treatment induces a much-
exaggerated ECL-cell hyperplasia and hypertrophy in the PCS rats, compared with
sham-operated animals [81]. The reason for this finding is unknown. From these
observations, it would seem that gastrin is the major stimulus of the ECL cells and
thatvagal denervation and PCS alter the way that the ECL cells respond to gastrin.
CONCLUDING COMMENTS
From the observations described above, it istempting to suggest that the ECLcells
represent agastrin target ofmajor physiological importance. The trophic response of
the rat ECLcell togastrin is spectacular, i.e., a four- tofivefold increase in numberas
compared with, at most, a 30 percent increase in the oxyntic mucosa as a whole in
response to long-term hypergastrinemia [82]. No other endocrine cell type in the
oxyntic mucosa seems to respond togastrin with stimulated growth.
REFERENCES
1. Forsmann WG, Orci L, Pictet R, Renold AE, Rouiller C: The endocrine cells in the epithelium ofthe
gastrointestinal mucosa ofthe rat. An electron microscope study. J Cell Biol 40:692-715, 1969
2. Solcia E, Vassallo G, Capella C: Cytology and cytochemistry ofhormone producing cells ofthe upper
gastrointestinal tract. In Origin, Chemistry, Physiology and Pathophysiology of the Gastrointestinal
Hormones. Edited byW Creutzfeld. Stuttgart, Germany, Schattauer, 1970, pp 3-29
3. Solcia E, Capella C, Vassallo G, Buffa R: Endocrine cells of the gastric mucosa. Int Rev Cytol
42:223-286, 1975
4. Capella C, Vassallo G, Solcia E: Light and electron microscopicidentification ofthe histamine-storing
argyrophil (ECL) cell in murine stomach and of its equivalent in other mammals. Z Zellforsch
118:68-84, 1971
5. Capella C, Finzi G, Cornaggia M, Usellini L, Luinetti 0, Buffa R, Solcia E: Ultrastructural typing of
gastric endocrine cells. In The Stomach as an Endocrine Organ. Fernstrom Symposium No 15. Edited
by R Hakanson, F Sundler. Amsterdam, The Netherlands, Elsevier, 1991, pp 27-51
6. H'akanson R, Owman C, Sporrong B, Sundler F: Electron microscopic identification ofthe histamine-
storing argyrophil (enterochromaffin-like) cells in the rat stomach. Z Zellforsch 122:460-466, 1971
7. Sundler F, Hakanson R: Peptide hormone-producing endocrine-paracrine cells in the gastro-entero-
pancreatic region. In Handbook ofChemical Neuroanatomy, Vol 6, The Peripheral Nervous System.
Edited by A Bjorklund, T H6kfelt, C Owman. Amsterdam, The Netherlands, Elsevier Science
Publishers, 1988, pp 219-295
8. Sundler F, Hakanson R: Gastric endocrine cell typing at the light microscopic level. In The Stomach
as an Endocrine Organ. Fernstrom Symposium No 15. Edited by RHakanson, F Sundler. Amsterdam,
The Netherlands, Elsevier, 1991, pp 9-26
9. Hakanson R, Bottcher G, Ekblad E, Panula P, Simonsson M, Dohlsten M, Hallberg T, Sundler F:
Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine
antibodies. Histochemistry 86:5-17, 1986
10. D'Adda T, Bertele A, Pilato FP, Bordi C: Quantitative electron microscopy of endocrine cells in
oxyntic mucosa ofhuman stomach. Cell Tissue Res 255:41-48, 1989
11. Simonsson M, Eriksson S, Hakanson R, Lind T, Lonroth H, Lundell L, O'Connor T, Sundler F:772 HAKANSON ET AL.
Endocrine cells in the human oxyntic mucosa. A histochemical study. Scand J Gastroenterol
23:1089-1099, 1988
12. Lonroth H, Hakanson R, Lundell L, Sundler F: Histamine-containing endocrine cells in the human
stomach. Gut 31:383-388, 1990
13. Bottcher G, H'akanson R, Nilsson G, Seensalu R, Sundler F: Effects oflong-term hypergastrinaemia
on the ultrastructure ofenterochromaffin-like cells in the stomach ofthe rat, hamster and guinea pig.
Cell Tiss Res 256:247-257, 1989
14. Hakanson R, Owman C: Concomitant demonstration ofhistamine and catecholamines in enterochro-
maffin-like cells ofgastric mucosa. Life Sci 6:759-766, 1967
15. Kubota H, Taguchi Y, Tohyama M, Shiosaka S, Ishihara T, Watanabe T, Shiotani Y, Wada H:
Electron microscopic identification of histidine decarboxylase-containing endocrine cells of the rat
gastric mucosa. Gastroenterology 87:496-502, 1984
16. Hakanson R, Ekelund M, Sundler F: Activation and proliferation of gastric endocrine cells. In
Evolution and Tumour Pathologyofthe Neuroendocrine System. Fernstrom Symposium No 4. Edited
by S Falkmer, RHikanson, F Sundler. Amsterdam, The Netherlands, Elsevier, 1984, pp 371-398
17. Hakanson R, Oscarson J, Sundler F: Gastrin and the trophic control of the oxyntic mucosa. Scand J
Gastroenterol 21 (Supplement 118): 18-30, 1986
18. Hgkanson R, Sundler F: Proposed mechanism of induction of gastric carcinoids: The gastrin
hypothesis. EurJ Clin Invest 20 (Supplement 1):65-71, 1990
19. H'akanson R, Sundler F: The gastrin concept: The proposed mechanism behind the development of
drug-induced gastric carcinoids. In The Stomach as an Endocrine Organ. Fernstrom Symposium No
15. Edited by R Hakanson, F Sundler. Amsterdam, The Netherlands, Elsevier, 1991, pp 449-460
20. Alumets J, El Munshid HA, Hakanson R, Liedberg G, Oscarson J, Rehfeld JF, Sundler F: Effect of
antrum exclusion on endocrine cells of rat stomach. J Physiol 286:145-155, 1979
21. Ryberg B, Carlsson E, Carlsson K, H'akanson R, Lundell L, Mattsson H, Sundler F: Effects ofpartial
resection of acid-secreting mucosa on plasma gastrin and enterochromaffin-like cells in the rat
stomach. Digestion 45:102-108, 1990
22. Hakanson R, Larsson LI, Liedberg G, Oscarson J, Sundler F, Vang J: Effects of antrectomy or
portacaval shunting on the histamine-storing endocrine-like cells in oxyntic mucosa of rat stomach. A
fluorescence histochemical, electron microscopic and chemical study. J Physiol 259:785-800, 1976
23. Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, Wallmark B, Watanabe T,
Hakanson R: Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation.
Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90:391-
399, 1986
24. Larsson H, Carlsson E, Hgkanson R, Mattsson H, Nilsson G, Seensalu R, Wallmark B, Sundler F:
Time-course ofdevelopment and reversal ofgastric endocrine cell hyperplasia after inhibition ofacid
secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology
95:1477-1486, 1988
25. Ryberg B, Bishop AE, Bloom SR, Carlsson E, Hakanson R, Larsson H, Mattsson H, Polak JM,
Sundler F: Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally
effective incausinghyperplasiaofenterochromaffin-like cellsin ratstomach. Regul Pept25:235-246,1989
26. Ryberg B, Axelson J, Hakanson R, Sundler F, Mattsson H: Trophic effects of continuous infusion of
(Leul5)-gastrin-17 in the rat. Gastroenterology 98:33-38, 1990
27. Tielemans Y, Hakanson R, Sundler F, Willems G: Proliferation of enterochromaffin-like cells in
omeprazole-treated hypergastrinemic rats. Gastroenterology 96:723-729, 1989
28. Tielemans Y, Willems G, Sundler F, Hgkanson R: Self replication of enterochromaffin-like cells in
the mouse stomach. Digestion 45:138-146, 1990
29. Tielemans Y, Axelson J, Sundler F, Willems G, Hakanson R: Serum gastrin concentration affects the
selfreplication rate ofthe enterochromaffin-like cells in the rat stomach. Gut 31:274-278, 1990
30. Ryberg B, Tielemans Y, Axelson J, Carlsson E, Hgkanson R, Mattsson H, Sundler F, Willems G:
Gastrin stimulates the self-replication rate of the enterochromaffin-like cells in the rat stomach.
Effects of omeprazole, ranitidine and gastrin-17 in intact and antrectomized rats. Gastroenterology
90:935-942, 1990
31. Wallmark B, Skanberg I, Mattsson H, Andersson K, Sundler F, Hakanson R, Carlsson E: Effect of20
weeks' ranitidine treatment on plasma gastrin levels and gastric enterochromaffin-like cell density in
the rat. Digestion 45:181-188, 1990
32. Tielemans Y, H'akanson R, Willems G: Hyperplastic manifestations of enterochromaffin-like cells in
the stomach ofrats with congenital moderate hypergastrinemia. Scand J Gastroenterol, in pressBIOLOGY AND PATHOBIOLOGY OF THE ECL CELLS 773
33. Streett CS, Cimprich RE, Robertson JL: Pathologic findings in the stomachs of rats treated with the
H2-receptor antagonist tiotidine. Scand J Gastroenterol 19 (Supplement 101):109-117, 1984
34. Streett CS, Robertson JL, Crissman JW: Morphologic stomach findings in rats and mice treated with
H2-receptor antagonist ICI 125, 211 and ICI 162, 846. Toxicol Pathol 16:299-304, 1988
35. Brittain RT, Jack D, Reeves JJ, Stables R: Pharmacological basis for the induction ofgastriccarcinoid
tumours in the rat by loxtidine, an unsurmountable histamine H2-receptor blocking drug. Br J
Pharmacol 85:843-847, 1985
36. Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C: Toxicological studies on omeprazole. Scand J
Gastroenterol 20 (Supplement 108):53-96, 1985
37. Poynter D, Pick CR, Harcourt RA, Selway SAM, Ainge G, Harman IW, Spurling NW, Fluch PA,
Cook IL: Association of long lasting unsurmountable histamine H2-blockade and gastric carcinoid
tumours in the rat. Gut 26:1284-1295, 1985
38. Betton GR, Salmon GK: Neuroendocrine (carcinoid) tumors of the glandular stomach of the rat
following treatment with an H2-receptor antagonist. Arch Toxicol 9:471-480, 1986
39. Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P: Gastric ECL-cell hyperplasia and
carcinoids in rodents following chronic administration of H2-receptor antagonist SK&F 93479 and
oxmetidine and omeprazole. Toxicol Pathol 16:288-298, 1988
40. Havu N: Enterochromaffin-like cell carcinoid of gastric mucosa in rats after lifelong inhibition of
gastric acid secretion. Digestion 35 (Supplement 1):42-55, 1986
41. Hirth RS, Evans LD, Buroker RA, Oleson FB: Gastric enterochromaffin-like cell hyperplasia and
neoplasia in rats: An indirect effect ofthe histamine H2-receptor antagonist, BL-6341. Toxicol Pathol
16:273-287, 1988
42. Spencer AJ, Barbolt TA, Henry DC, Eason CT, Saverschell RJ, Bonner FW: Gastric morphological
changes including carcinoid tumours in animals treated with a potent hypolipidaemic agent, ciprofi-
brate. Toxicol Pathol 17:7-15, 1989
43. Havu N, Mattsson H, Ekman L, Carlsson E: Enterochromaffin-like cell carcinoids in the rat gastric
mucosa following long-term administration ofranitidine. Digestion 45:189-195, 1990
44. Creutzfeldt W: The achlorhydria-carcinoid sequence: Role ofgastrin. Digestion 39:61-79, 1988
45. Carlsson E, Havu N, Mattsson H, Ekman L, Ryberg B: Gastric carcinoids in rats treated with
inhibitorsofgastric acid secretion. InThe Stomach as an Endocrine Organ. Fernstrom Symposium No
15. Edited by RHakanson, F Sundler. Amsterdam, The Netherlands, Elsevier, 1991, pp 461-471
46. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E: Partial gastric corpectomy
results in hypergastrinaemia and development ofgastric enterochromaffin-like cell carcinoids in the
rat. Gastroenterology 100:311-319, 1991
47. Hollander D, Tarnawski A, Stachura J, Gergely H: Morphologic changes in gastric mucosa of aging
rats. Dig Dis Sci 34 (11):1692-1700, 1989
48. MajkaJA, Sher S: Spontaneousgastric carcinoid tumor in an aged Sprague-Dawley rat. Vet Pathology
26:88-90, 1989
49. Rubin W: Proliferation of endocrine-like (enterochromaffin) cells in atrophic gastric mucosa.
Gastroenterology 57:641-648, 1969
50. Rubin W: A fine structural characterization of the proliferated endocrine cells in atrophic gastric
mucosa. Am J Pathol 70:109-118, 1973
51. BordiC, CostaA, Missale G: ECLcellproliferation andgastrin levels. Gastroenterology 68:205-206,1975
52. Wilander E: Achylia, pernicious anaemia, ECL cells and gastric carcinoids. Virchows Arch (A Pathol
Anat Histol) 387:372-373, 1980
53. Borch K, Renvall H, LiedbergG: Endocrine cell proliferation and carcinoid development: Areviewof
new aspects ofhypergastrinemic atrophic gastritis. Digestion 35 (Supplement 1):106-115, 1986
54. Borch K: Atrophic gastritis andgastric carcinoid tumours. Ann Med 21:291-297, 1989
55. Rode J, Dhillon AP, Papadaki L, Stockbrugger R, Thompson RJ, Moss E, Cotton PB: Pernicious
anaemia and mucosal endocrine cell proliferation ofthe non-antral stomach. Gut 27:789-798, 1986
56. Cattan D, Roucayrol AM, LaunayJM, Callabert J, Courillon-Mallet A: Serum gastrin and argyrophil
cell hyperplasia relationships in fundic atrophic gastritis. In The Stomach as an Endocrine Organ.
Fernstrom Symposium No 15. Edited by R Hakanson, F Sundler. Amsterdam, The Netherlands,
Elsevier, 1991, pp 425-448
57. Carney JA, Go VL, Fairbanks VF, Moore SB, Alport EC, Nora FE: The syndrome of gastric
argyrophil carcinoid tumors and non-antral gastric atrophy. Ann Intern Med 99:761-766, 1983
58. Bordi C, Pilato F, Carfagna G, Ferrari D, D'Adda T, Sivelli R, Bertele A, Missale G: Argyrophil cell
hyperplasia of fundic mucosa in patients with chronic atrophic gastritis. Digestion 35 (Supplement
1):130-143, 1986774 HAKANSON ET AL.
59. Bordi C, Cocconi C, Togni R, Vezzadini P, Missale G: Gastric endocrine cell proliferation. Associa-
tion with the Zollinger-Ellison syndrome. Arch Pathol 98:274-278, 1974
60. Solcia E, Capella C, Sessa F, Rindi G, Cornaggia M, Riva C, Villani L: Gastric carcinoids and related
endocrine growths. Digestion 35 (Supplement 1):3-22, 1986
61. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J: Gastric argyrophil carcinoidosis in patients with
Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized associa-
tion. Am J Surg Pathol 14:503-513, 1990
62. Richards AT, Hinder RA, Harrison AC: Gastric carcinoid tumours associated with hypergastrinae-
mia and pernicious anaemia-regression oftumours by antrectomy. S Afr Med J 72:51-53, 1987
63. Eckhauser JE, Lloyd RV, Thompson NW, Raper SE, Vinik AI: Antrectomy for multicentric,
argyrophil gastric carcinoids: Apreliminary report. Surgery 104:1046-1053, 1988
64. Lundell L, Olbe L, Sundler F, Simonsson M, Hakanson R: Reversibility of multiple ECL-cell gastric
carcinoids by antrectomy in a pernicious anemia patient. Hepatogastroenterology 36:43-44, 1989
65. Hirschowitz B, Griffith J, Pellegrin D, Cummings OW: Rapid regression ofenterochromaffin-like cell
gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 102:1409-1418, 1992
66. Tielemans Y, Chen D, Sundler F, Hakanson R, Willems G: Reversibility of the cell kinetic changes
induced byomeprazole in the rat oxyntic mucosa. Scand J Gastroenterol 27:155-160, 1992
67. Hakanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F: Time-dependent changes
in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology, in press
68. Andersson K, Hakanson R, Mattsson H, Ryberg B, Sundler F: Hyperplasia of histamine-depleted
enterochromaffin-like cells in rat stomach using omeprazole and a-fluoromethylhistidine. Gastroen-
terology 103:897-904, 1992
69. Kollonitsch J, Perkins LM, Patchett AA, Doldouras GA, Marburg S, Duggan DE, MaycockAL, Aster
SD: Selective inhibitors ofbiosynthesis ofaminergic neurotransmitters. Nature 274:906-908, 1978
70. Andersson K, Chen D, Hakanson R, Mattsson H, Sundler F: Enterochromaffin-like cells in the rat
stomach: Effect of a-FMH-evoked histamine depletion. A chemical, histochemical and electron
microscopic study. Cell Tissue Res 270:7-13, 1992
71. Park J, Chiba T, Yamada T, Yakabi K: Cholecystokinin (CCK) stimulates somatostatin release from
isolated canine gastric D-cells via both gastrin and CCK-selective receptors. Gastroenterology
92:1566, 1987
72. Chen D, Uribe A, Hakanson R, Sundler F: Somatostatin cells in the oxyntic mucosa of hypo- or
hypergastrinemic rats. Scand J Gastroenterol 27:479-482, 1992
73. Soll AH, Amirian DA, Park J, Elashoff JD, Yamada T: Cholecystokinin potently releases somato-
statin from canine fundic mucosal cells in short-term culture. Am J Physiol 248:G569-G599, 1985
74. Roche S, Gusdinar T, Bali J-P, Magous R: "Gastrin" and "CCK" receptors on histamine- and
somatostatin-containing cells from rabbit fundic mucosa-I. Characterization by means of agonists.
Biochem Pharmacol 42:765-770, 1991
75. Roche S, Gusdinar T, Bali J-P, Magous R: "Gastrin" and "CCK" receptors on histamine- and
somatostatin-containing cells from rabbit fundic mucosa-II. Characterization by means of selective
antagonists (L-364,718 and L-365,260). Biochem Pharmacol 42:771-776, 1991
76. Nylander A-G, Chen D, Lilja I, Axelson J, Ihse I, Rehfeld JF, Sundler F, Hakanson R: The ECL cells
in the rat stomach respond to short term infusion ofhigh doses ofCCKbut not to long-term sustained,
moderate hyperCCKemia by continuous cholecystokinin infusion or pancreaticobiliary diversion.
Scand J Gastroenterol 28:73-79, 1993
77. Hakanson R, Vallgren S, Ekelund M, Rehfeld JF, Sundler F: The vagus exerts trophic control of the
stomach in the rat. Gastroenterology 86:28-32, 1984
78. Axelson J, Ekelund M, Hgkanson R, Sundler F: Gastrin and the vagus interact in the trophic control
ofthe rat oxyntic mucosa. Regul Pept 22:237-243, 1988
79. Hakanson R, Axelson J, Tielemans Y, Johansson A-G, Willems G, Sundler F: Unilateral vagal
denervation suppresses omeprazole-induced trophic effects on the denervated side ofthe rat stomach.
Scand J Gastroenterol 27:65-70, 1991
80. Ekelund M, H'akanson R, Holmin T, Oscarson J, Rehfeld JF, Sundler F, Westrin P: Effects of
portacaval shunt on the rat stomach. Acta Physiol Scand 124:437-447, 1985
81. Axelson J, Ekelund M, Hakanson R, Sundler F: Enhanced hyperplasia ofgastricenterochromaffinlike
cells in response toomeprazole-evoked hypergastrinemia in ratswith portacaval shunt. An immunocy-
tochemical and chemical study. Gastroenterology 99:635-640, 1990
82. H'akanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F: Hypergastrinemia produces
trophic effects on the stomach but not in pancreas and intestines. Regul Pept 13:225-233, 1986